胃肠道间质瘤（GIST）患者的医学肿瘤治疗 - 系统评价。
Medical oncological treatment for patients with Gastrointestinal Stromal Tumor (GIST) - A systematic review.
机构信息
Department of Oncology, Copenhagen University Hospital, Herlev and Gentofte Hospital, Borgmester Ib Juuls Vej 1, DK-2730 Herlev, Denmark.
Department of Oncology, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, DK-8200 Aarhus, Denmark.
出版信息
Crit Rev Oncol Hematol. 2022 Apr;172:103650. doi: 10.1016/j.critrevonc.2022.103650. Epub 2022 Mar 10.
BACKGROUND
Chemotherapy is ineffective in treating patients with Gastrointestinal Stromal Tumor (GIST). However, several types of tyrosine kinase inhibitors have been investigated since the approval of imatinib in 2001. The purpose of this report was to systematically review studies on the efficacy of neoadjuvant, adjuvant, and lifelong medical oncological treatment of GIST.
METHODS
The Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines were followed throughout the review process. The protocol was submitted to the International prospective register of systematic reviews database (ID 251724). A systematic literature search was performed, including phase II- and III studies of biological treatment, reporting on treatment effect in patients with GIST.
RESULTS
Of 308 identified publications, 42 studies were included in this review.
CONCLUSION
This review gives an overview of the existing evidence for approved lines of oncological treatments and potential alternatives for patients with GIST in the neoadjuvant-, adjuvant- and life-long setting.
背景
化疗在治疗胃肠道间质瘤（GIST）患者方面无效。然而，自 2001 年批准伊马替尼以来，已经研究了几种类型的酪氨酸激酶抑制剂。本报告的目的是系统地回顾新辅助、辅助和终身肿瘤内科治疗 GIST 的疗效研究。
方法
在整个审查过程中都遵循了系统评价和荟萃分析的首选报告项目指南。该方案已提交给国际前瞻性系统评价登记数据库（ID 251724）。进行了系统的文献检索，包括生物治疗的 II 期和 III 期研究，报告了 GIST 患者的治疗效果。
结果
在 308 篇已确定的出版物中，有 42 篇研究被纳入本综述。
结论
本综述概述了新辅助、辅助和终身治疗环境中 GIST 患者现有批准的肿瘤内科治疗方法和潜在替代方法的证据。
Zotero 插件